Close Menu

NEW YORK (GenomeWeb) – Biodesix today announced that Health Net has issued a positive coverage decision for the VeriStrat test. 

According to Biodesix, Health Net considers the test medically necessary for patients with advanced non-small cell lung cancer and wild-type EGFR or with unknown EGFR status. Health Net covers about 5.9 million lives, primarily on the US West Coast. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.